Absorption, distribution, metabolism, elimination (ADME)

Active pharmaceutical ingredient (API)

Adaptive trial

Ames test

Antibiotic, antibacterial and antimicrobial

Antimicrobial resistance (AMR)

Antimicrobial susceptibility testing (AST), resistance testing

Antiseptic

Bacterial efflux

Bacterial target

Bactericidal

Bacteriostatic

Breakpoint concentration, clinical

Candidate

Chemistry, manufacturing and controls (CMC)

Clinical Development

Cmax

Drug product, medicinal product

Epidemiological cut-off value (ECOFF)

ESKAPE

Extensively drug-resistant (XDR)

High-throughput screen (HTS)

Hit

Hit confirmation, hit validation

Hit expansion

Hit identification, hit discovery

Hit-to-lead (HTL), lead generation

Intracellular concentration

Investigational new drug (IND)

Lead compound

Lead optimization

Limited population pathway for antimicrobial and antifungal drugs (LPAD)

Lipophilicity

LogD

LogP

Marketing authorization application (MAA)

Maximum tolerated dose (MTD)

Mechanism of action (MoA)

Median effective dose (ED50)

Median lethal dose (LD50)

Medicinal chemistry

Minimum inhibitory concentration (MIC)

Multidrug-resistant (MDR)

Natural products

New chemical entity (NCE), new molecular entity (NME)

New drug application (NDA)

Non-inferiority margin

Non-inferiority trial

Pandrug-resistant (PDR)

Pharmacodynamics (PD)

Pharmacokinetics (PK)

Pharmacokinetics-pharmacodynamics (PK/PD)

Pharmacovigilance

Phase 1, 2, 3, 4 trials

Placebo-controlled trial

Plasma concentration

Plasma protein binding

Preclinical development

Pro-drug

Qualified infectious disease product (QIDP)